Protagonist Therapeutics
PTGX
PTGX
148 hedge funds and large institutions have $1.67B invested in Protagonist Therapeutics in 2021 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 59 increasing their positions, 35 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
69% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 35
12% more funds holding
Funds holding: 132 → 148 (+16)
6.01% more ownership
Funds ownership: 97.59% → 103.59% (+6%)
Holders
148
Holding in Top 10
8
Calls
$46.3M
Puts
$19.9M
Top Buyers
| 1 | +$40.9M | |
| 2 | +$28.9M | |
| 3 | +$19.1M | |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$16.9M |
| 5 |
SC
Samlyn Capital
New York
|
+$15.4M |
Top Sellers
| 1 | -$67.3M | |
| 2 | -$16.2M | |
| 3 | -$12.5M | |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$12.5M |
| 5 |
Goldman Sachs
New York
|
-$10.2M |